PolyPid Ltd. (PYPD) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.4x

Market Cap

$110.29M

MomentumView details →

1D Return

+3.04%

YTD Return

+23.16%

RSI (14)

63.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.4x

Market Cap

$110.29M

RSI (14)

63.8

MomentumView details →

1D Return

+3.04%

YTD Return

+23.16%

SummaryUpdated Jun 1, 2026

PolyPid Ltd. (NASDAQ:PYPD) is an Israeli late-stage biopharmaceutical company founded in 2008 and headquartered in Petah Tikva, Israel. The company went public in June 2020 and focuses on developing innovative drug delivery solutions using its proprietary polymer-lipid encapsulation matrix (PLEX) platform technology. PolyPid is currently in Phase III clinical trials with its lead product candidate D-PLEX100, designed to prevent surgical site infections, representing a significant unmet medical need in healthcare settings.

Ask drillr about PolyPid Ltd. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−584.65%

ROA (TTM)

−206.78%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+61.36%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+57.43%

EBITDA YoY

+5.59%

EarningsView details →

EPS (Actual)

−$0.35

EPS Surprise

7.28%

Beats (12Q)

7/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

10.93%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

1.35x

Quick Ratio

1.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−31.50M

Op. CF (TTM)

0.00

Next earningsNov 11, 2026 →

Latest newsMore news →

No recent news for PYPD.

Similar companies

Fractyl Health, Inc. Common StockGUTS RenovoRx, Inc.RNXT Coya Therapeutics, Inc.COYA Genelux CorporationGNLX Seer, Inc.SEER ProMIS Neurosciences, Inc.PMN Find similar companies →

Latest newsMore news →

No recent news for PYPD.